Yahoo Finance

Estimated Discount To Fair Value: 29.3%

Haisco Pharmaceutical Group's current trading price of CN¥39.36 is substantially below its fair value estimate of CN¥55.7, indicating it is undervalued based on cash flow analysis. The company reported significant revenue growth to CN¥2.75 billion for the nine months ending September 2024, up from CN¥2.38 billion a year prior, with net income rising to CN¥381.82 million from CN¥200.74 million, despite low dividend coverage by free cash flows and moderate return on equity projections.

• Our earnings growth report unveils the potential for significant increases in Haisco Pharmaceutical Group's future results.

• Dive into the specifics of Haisco Pharmaceutical Group here with our thorough financial health report.

Bora Pharmaceuticals

Overview: Bora Pharmaceuticals Co., LTD. is involved in the research, development, manufacturing, distribution, and sale of pharmaceuticals globally with a market cap of NT$88.87 billion.

Operations: The company's revenue is primarily derived from the Sales Operations Department at NT$14.08 billion and the CDMO Operations Department at NT$6.33 billion.

Estimated Discount To Fair Value: 39.4%

Bora Pharmaceuticals' current trading price of NT$860 is significantly below its estimated fair value of NT$1,419.83, indicating an undervaluation based on cash flow analysis. The company reported third-quarter sales of TWD 5.61 billion, up from TWD 3.08 billion a year ago, with net income increasing to TWD 1.45 billion from TWD 733 million. Despite high revenue growth forecasts and earnings expansion by 36% last year, debt coverage by operating cash flow remains weak.

• Our expertly prepared growth report on Bora Pharmaceuticals implies its future financial outlook may be stronger than recent results.

• Navigate through the intricacies of Bora Pharmaceuticals with our comprehensive financial health report here.

Seize The Opportunity

• Explore the 920 names from our Undervalued Stocks Based On Cash Flows screener here.

• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.

• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SHSE:688275 SZSE:002653 and TWSE:6472.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com